Treatment outcome of multidrug resistant tuberculosis with second line drugs

A. Sorete Arbore, V. Cojocariu (Iasi, Romania)

Source: Annual Congress 2001 - Problems in treatment of TB
Session: Problems in treatment of TB
Session type: Thematic Poster Session
Number: 2072
Disease area: Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Sorete Arbore, V. Cojocariu (Iasi, Romania). Treatment outcome of multidrug resistant tuberculosis with second line drugs. Eur Respir J 2001; 16: Suppl. 31, 2072

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Second and third line anti-tuberculosis drug's side effects during the treatment of patients with multidrug resistant tuberculosis (MDR TB)
Source: Eur Respir J 2003; 22: Suppl. 45, 555s
Year: 2003

Treatment outcome of multi-drug resistant tuberculosis
Source: Annual Congress 2004 - Problems of resistance and HIV coinfection in tuberculosis
Year: 2004


Treatment possibilities of multi-drug resistant (MDR) tuberculosis
Source: Eur Respir J 2003; 22: Suppl. 45, 525s
Year: 2003

Evaluation of characteristics and treatment results of patients treated as multidrug resistant tuberculosis
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012

Side effect profile of 2nd line drugs in multi drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis
Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Year: 2015


Efficacy of empiric chemotherapy regimen in patients with multidrug resistant (MDR) tuberculosis
Source: Eur Respir J 2004; 24: Suppl. 48, 656s
Year: 2004

Treatment of resistant tuberculosis in patients having isolates resistant to multiple antituberculosis drugs
Source: Annual Congress 2010 - Prognosis of tuberculosis
Year: 2010

Treatment of multidrug resistant pulmonary tuberculosis (MDR-TB) with different pattern of resistance
Source: Eur Respir J 2004; 24: Suppl. 48, 723s
Year: 2004

Our experience in multi drug resistant tuberculosis (MDR TB) treatment
Source: Eur Respir J 2005; 26: Suppl. 49, 652s
Year: 2005

Short course of chemotherapy of multidrug resistant tuberculosis (MDR TB)
Source: Eur Respir J 2004; 24: Suppl. 48, 722s
Year: 2004

Treatment results of multidrug resistant pulmonary tuberculosis (MDR-TB)
Source: Eur Respir J 2005; 26: Suppl. 49, 199s
Year: 2005

Unit of multidrug resistant tuberculosis - effect of treatment
Source: Eur Respir J 2002; 20: Suppl. 38, 614s
Year: 2002

A case with new case multidrug resistant cranial and pulmonary tuberculosis successfully treated with major antituberculous drugs
Source: Eur Respir J 2004; 24: Suppl. 48, 651s
Year: 2004

Outcomes of patients with multidrug resistant tuberculosis
Source: Eur Respir J 2005; 26: Suppl. 49, 652s
Year: 2005

Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB
Source: Eur Respir J 2009; 33: 581-585
Year: 2009



Treatment results of multidrug resistant tuberculosis and the factors affecting treatment results
Source: Annual Congress 2008 - Epidemiological and clinical aspects of tuberculosis control
Year: 2008

Multidrug resistant tuberculosis (MDR – TB) treatment outcomes in Iran
Source: Eur Respir J 2004; 24: Suppl. 48, 657s
Year: 2004

Cost-effectiveness analysis of regimens chemotherapy in patients with multidrug resistant tuberculosis (MDR TB) compared with standard regimen in patients with susceptible MBT
Source: Eur Respir J 2003; 22: Suppl. 45, 526s
Year: 2003

The surgery of multidrug resistant tuberculosis
Source: Eur Respir J 2003; 22: Suppl. 45, 556s
Year: 2003

Adverse effects of second-line drugs during the treatment of multidrug resistant tuberculosis patients
Source: Eur Respir J 2005; 26: Suppl. 49, 650s
Year: 2005